2025国谈新进展：专家评审结束 近期召开企业沟通会

Core Insights - The National Healthcare Security Administration (NHSA) announced the completion of expert reviews for the 2025 National Basic Medical Insurance Directory and the Commercial Health Insurance Innovative Drug Directory, marking the 8th adjustment since the NHSA's establishment and the first inclusion of a commercial insurance innovative drug directory [1][2] Group 1: Directory Adjustments - A total of 534 drugs were reviewed for inclusion in the basic medical insurance directory, while 121 drug generic names were reviewed for the commercial health insurance innovative drug directory, including high-priced innovative drugs like CAR-T therapy [1] - The NHSA's announcement indicates that drugs marked for "proposed negotiation," "proposed bidding," and "proposed price consultation" are eligible for negotiation or bidding but do not guarantee inclusion in the directories [1] Group 2: Negotiation and Communication - Following the expert review, the next phase will involve negotiation, bidding, and price consultation, where companies must submit relevant materials for assessment by the NHSA [2] - The NHSA plans to hold a face-to-face communication meeting in Beijing with companies involved in negotiations, bidding, and price consultations to discuss evaluation methods and gather feedback [2] - The timeline for this year's negotiations is tighter compared to previous years, with companies required to submit materials by September 30, 2023, following the announcement on September 20, 2023 [2]